# Cerevance

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cerevance

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.cerevance.com/
- Total disclosed funding: $205M
- Latest round: Series C (May 12, 2026)
- Investors on record: 15

## About

Established in 2016 and based in Massachusetts, US, Cerevance, LLC researches and develops therapeutics for the treatment of neurological and psychiatric disorders. The company was co-founded by Brad Margus. In May 2026, Cerevance, LLC raised USD 20 million in series C funding from Double Point Ventures, Gates Frontier, Google Ventures, Lightstone Ventures, MQB Partners, SV Health Investors, and UPMC Enterprises.

The company specializes in developing therapies for central nervous system (CNS) disorders using its proprietary NETSseq platform. This advanced technology utilizes human data and machine learning to identify targets in single cell types or those altered by disease, allowing for precision in treatment development. Cerevance's approach provides therapeutic options with minimal off-target effects, addressing some of the CNS conditions. The company’s pipeline, including the ASCEND study for Parkinson's disease, is at the forefront of precision neuroscience and CNS disorder treatment.

The company will use the May 2026 funding to support completion of its Phase 3 trial and advance its pipeline while extending its operational runway into mid-2027.

## Funding rounds

- Series C, May 12, 2026, $20M — SV Health Investors, GV, Lightstone Ventures, Gates Frontier, Double Point Ventures, UPMC Enterprises
- Series B, Apr 25, 2024, $47M — GV, Lightstone Ventures, Agent Capital, Gates Frontier, Bioluminescence Ventures, Double Point Ventures, LifeRock Ventures
- Series B, Feb 13, 2023, $51M — GV, Foresite Capital, Takeda Ventures, Lightstone Ventures, Dolby Family Ventures, UPMC Enterprises, Dementia Discovery Fund, Gates Frontier
- Series B, Jul 20, 2020, $20M — GV, Casdin Capital, Takeda Ventures, Lightstone Ventures, Dolby Family Ventures, UPMC Enterprises, Dementia Discovery Fund
- Series B, Apr 14, 2020, $45M — SV Health Investors, GV, Foresite Capital, Takeda Ventures, Lightstone Ventures
- Series A, Dec 2, 2016, $22M — Lightstone Ventures, Takeda Pharmaceutical

## Investors

- Lightstone Ventures (https://capitalatlas.ai/funds/lightstone-ventures) — Series A, Series B, Series C
- Takeda Pharmaceutical — Series A
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series B, Series C
- GV (https://capitalatlas.ai/funds/gv) — Series B, Series C
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series B
- Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B
- Dolby Family Ventures (https://capitalatlas.ai/funds/dolby-family-ventures) — Series B
- UPMC Enterprises (https://capitalatlas.ai/funds/upmc-enterprises) — Series B, Series C
- Dementia Discovery Fund — Series B
- Gates Frontier — Series B, Series C
- Agent Capital (https://capitalatlas.ai/funds/agent-capital) — Series B
- Bioluminescence Ventures (https://capitalatlas.ai/funds/bioluminescence-ventures) — Series B
- Double Point Ventures (https://capitalatlas.ai/funds/double-point-ventures) — Series B, Series C
- LifeRock Ventures — Series B